CA002 / Camallergy - LARVOL DELTA

[VIRTUAL] Alternatives to medication for the prevention of aggression by psycho geriatric patients: The challenge to adopt a new protocol . (AAIC 2021) - "The product is registered in the European Union as a medical device Class I: NL-CA002-2017-42023...However the hesitance of some managers to break with old protocols and try out something new was the reason to cancel the trial. We are looking for organizations (nursing homes, psychogeriatric hospitals etc) that can test this medical device."

Clinical • Alzheimer's Disease • CNS Disorders • Dementia • Geriatric Disorders • Psychiatry

Camallergy Awarded £1.1 M Funding Under Innovate UK Biomedical Catalyst Award for Novel Peanut Allergy Treatment (Businesswire) - "Cambridge Allergy...today announced it has been awarded £1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom’s research and innovation agency...funding will be used to accelerate the Company’s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials...the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA."

Financing • Food Hypersensitivity

Camallergy’s UK Based Manufacturing Facility Receives cGMP Licences for Peanut Allergy Treatment (Businesswire) - "Cambridge Allergy...today announced that its manufacturing facility outside of Portsmouth, United Kingdom was approved by the MHRA, the Medicines and Healthcare products Regulatory Agency, to manufacture its proprietary peanut allergy treatment under current Good Manufacturing Practices (cGMP) standards...The new manufacturing facility will handle cGMP production of CA002, the Company’s proprietary peanut allergy treatment, for planned pivotal clinical trials...we are in position to pursue our IND (Investigational New Drug) and IMPD (Investigational Medicinal Product Dossier) applications in the US, UK, and EU to initiate our pivotal Phase 3 studies planned to commence this year..."

Commercial • New P3 trial • Food Hypersensitivity

Camallergy provides corporate update and prepares to advance lead candidate CA002 into phase 3 efficacy trial for peanut allergy (Businesswire) - "Cambridge Allergy Ltd...today provided a corporate update, including recent progress with its development of CA002 for the treatment of peanut allergy...Camallergy plans to initiate a randomized, double-blind, placebo-controlled Phase 3 clinical trial by mid-year 2020 to evaluate the efficacy and safety of CA002 as a treatment for peanut allergy."

New P3 trial